---
title: "Boston Commerce Limited (531458) — Share Price, Financials & Analysis"
symbol: "531458"
company: "Boston Commerce Limited"
canonical: "https://tapetide.com/stocks/531458"
isin: "INE109B01019"
nse_symbol: "BOSTONBIOSYSTEMSLTD"
bse_code: "531458"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 3.1
generated_at: "2026-09-13T18:37:24.077Z"
---

# Boston Commerce Limited (531458)

Canonical page: https://tapetide.com/stocks/531458

## Company

- **NSE Symbol:** BOSTONBIOSYSTEMSLTD
- **BSE Code:** 531458
- **ISIN:** INE109B01019
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** bostonbiosystemltd.com

## About

Incorporated in 1995, Boston Bio Systems 
Ltd is in the business of trading in goods 
e.g. Medical equipment, testing kits, 
 instruments etc.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:39:52.032474Z.

- **Market Cap:** ₹3.1 Cr
- **Classification:** Microcap
- **P/E (reported):** -5.4
- **EPS (TTM):** ₹-0.82
- **Book Value:** ₹7.6
- **Price to Book:** 0.59
- **Dividend Yield:** 0%
- **ROE:** -9.27%
- **ROCE:** -5.21%
- **Debt to Equity:** 0.18
- **Revenue (yearly):** ₹0.48 Cr
- **Net Income:** ₹-0.58 Cr
- **EBITDA:** ₹0.01 Cr
- **52-Week High:** ₹10.95
- **52-Week Low:** ₹4.01
- **RSI (14):** 41.79

## Tapetide Score

- **Score:** 56 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Fair · Momentum: Falling
- **Percentile:** 74.1 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 39.76 | 9% |
| growth | 98.9 | 9% |
| momentum | 36.57 | 12% |
| ownership | 50 | 24% |
| quality | 66.95 | 22% |
| valuation | 56.33 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Stock is trading at 0.63 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding is low: 2.14%
- Company has a low return on equity of -6.94% over last 3 years.
- Company's cost of borrowing seems high

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -4.59% | -4.59% | — |
| ebitda margin growth | -0.1% | -100.73% | — | — |
| net income growth | -0.6% | 16% | 480% | — |
| revenue growth | -100% | 140% | — | — |
| roce | — | 143.46% | — | -1.48% |
| roe | — | 325.23% | -3.83% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.19 | 0.18 | 0.24 | 0.06 | 0 |
| Expenses | 0 | 0 | 0 | 0.14 | 0 | 0.01 | 0.05 | 0.68 | 0.1 | 0.14 | 0.04 | 0.08 |
| Operating Profit | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.08 | 0.1 | 0.02 | -0.08 |
| OPM % | — | — | — | — | — | — | — | -257.89 | 44.44 | 41.67 | 33.33 | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.05 | 0.03 | 0.59 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.05 | 0.05 | -0.01 | -0.67 |
| Tax % | — | — | — | 0 | — | 0 | 0 | 0 | 20 | 20 | 0 | -4.48 |
| Net Profit | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.04 | 0.04 | -0.01 | -0.65 |
| EPS in Rs | 0 | 0 | 0 | -0.2 | 0 | -0.01 | -0.07 | -0.7 | 0.06 | 0.06 | -0.01 | -0.93 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.05 | 0.06 | 1.5 | 0.53 | 0.7 | 0 | 0 | 0 | 0.19 | 0.48 |
| Expenses | 0.05 | 0.06 | 1.5 | 0.53 | 0.7 | 0 | 0 | 0.14 | 0.74 | 0.47 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | 0.01 |
| OPM % | 0 | 0 | 0 | 0 | 0 | — | — | — | -289.47 | 2.08 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.59 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | -0.58 |
| Tax % | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | -0.58 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.2 | -0.79 | -0.83 |
| Dividend Payout % | — | — | — | — | — | — | — | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.41 | -0.41 | -0.55 | -1.1 | -1.68 |
| Borrowings | 0.12 | 0.12 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 5.44 | 0.96 |
| Other Liabilities | -0.01 | -0.01 | 1.46 | 1.9 | 2.6 | 3.11 | 3.11 | 3.25 | 3.57 | 1.09 |
| Total Liabilities | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
| Total Assets | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 0.97 | -0.03 | -0.02 | 0.13 | 0 | 0 | 0 | -4.59 | 5.12 |
| Cash from Investing Activity | 0 | -0.91 | 0 | 0 | -0.08 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.58 | -5.08 |
| Net Cash Flow | 0 | 0.06 | -0.03 | -0.02 | 0.05 | 0 | 0 | 0 | -0.01 | 0.04 |
| Free Cash Flow | 0 | 0.97 | -0.03 | -0.02 | 0.13 | 0 | 0 | 0 | -4.59 | 5.12 |
| CFO/OP | — | — | — | — | — | — | — | 0 | 835 | 51200 |

### Ratios

| Item | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 0 | 0 | 362.57 | 1342.92 | 1308.79 | — | — | — | 5532.63 | 0 |
| Inventory Days | — | — | 0 | 0 | 11.59 | — | — | — | — | — |
| Days Payable | — | — | — | — | 1488.97 | — | — | — | — | — |
| Cash Conversion Cycle | 0 | 0 | 362.57 | 1342.92 | -168.6 | — | — | — | 5532.63 | 0 |
| Working Capital Days | -876 | 4745 | 226.3 | 661.13 | 453.64 | — | — | — | 10585 | 836.46 |
| ROCE % | 0 | 0 | 0 | 0 | 0 | — | 0 | -1.89 | -5.89 | 0.11 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% | 2.14% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 1.7% | 1.7% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 85.14% | 85.14% | 85.14% | 85.14% | 85.14% | 85.14% | 84.78% | 85.33% | 85.21% | 84.81% | 81.75% | 80.5% |
| Others | 12.72% | 12.72% | 12.72% | 12.72% | 12.72% | 12.72% | 13.08% | 12.53% | 12.64% | 13.05% | 14.41% | 15.66% |
| No. of Shareholders | 1141 | 1141 | 1141 | 1141 | 1141 | 1141 | 1147 | 1295 | 1385 | 1410 | 1408 | 1447 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 5 / 6 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 4.84 | Sell |
| EMA (10) | 4.79 | Buy |
| SMA (20) | 4.78 | Buy |
| EMA (20) | 4.82 | Sell |
| SMA (50) | 5.01 | Sell |
| EMA (50) | 5.15 | Sell |
| SMA (100) | 6.01 | Sell |
| EMA (100) | 5.73 | Sell |
| SMA (200) | 6.66 | Sell |
| EMA (200) | 6.62 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 49 | Neutral |
| MACD (12,26,9) | -0.07 | Buy |
| Stochastic (14,3,3) | 50.81 | Neutral |
| ADX (14) | 28.35 | Buy |
| Williams %R (14) | -37.39 | Neutral |
| ATR (14) | 0.32 | High Volatility |
| ROC (12) | 2.55 | Buy |
| Stoch RSI (14) | 49.11 | Neutral |
| UO (7,14,28) | 62.41 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jan - Certificate under Regulation 74(5) of SEBI(Depositories and Participants)Regulations, 2018 for the quarter ended 31st December, 2025 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jan - Certificate under Regulation 74(5) of SEBI(Depositories and Participants)Regulations, 2018 for the quarter ended 31st December, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85415e1f-8b88-48ef-9964-d04a34615227.pdf) |
| 3h - EDQM granted CEP for Metformin Hydrochloride Process-II on 5 March 2026, adding to existing CEP. | [EDQM Issued CEP Certificate For 'METFORMIN HYDROCHLORIDE Process-II' 3h - EDQM granted CEP for Metformin Hydrochloride Process-II on 5 March 2026, adding to existing CEP.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/17acf643-a504-48ca-9cf7-a793070fcd5b.pdf) |
| 30 Mar - Trading window closed from 01-Apr-2026 until 48 hours after audited results for FY/Q4 ending 31-Mar-2026. | [Closure of Trading Window 30 Mar - Trading window closed from 01-Apr-2026 until 48 hours after audited results for FY/Q4 ending 31-Mar-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c7bd93e2-508b-4ad4-a50e-7fbdbe2a560a.pdf) |
| 30 Apr - Company says Annual Secretarial Compliance Report not applicable for FY2026 under Regulation 24A exemption. | [Non-Applicability Of Annual Secretarial Compliance Report For The Year Ended 31St March, 2026 Under Regulation 24A Of The SEBI (LODR) Regulations, 2015 30 Apr - Company says Annual Secretarial Compliance Report not applicable for FY2026 under Regulation 24A exemption.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cb1d6cbc-3a64-4cc0-a441-94d4eef90fee.pdf) |
| 30 Apr - Company says Annual Secretarial Compliance Report not applicable for FY2026 under Regulation 24A exemption. | [Non-Applicability Of Annual Secretarial Compliance Report For The Year Ended 31St March, 2026 Under Regulation 24A Of The SEBI (LODR) Regulations, 2015 30 Apr - Company says Annual Secretarial Compliance Report not applicable for FY2026 under Regulation 24A exemption.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/cb1d6cbc-3a64-4cc0-a441-94d4eef90fee.pdf) |
| 30 Apr - Boston Commerce says it is not a large corporate for FY2026; borrowings are below ₹1,000 crore. | [Non-Applicability Of Disclosure Of Large Corporate For The Year Ended 31St March, 2026 30 Apr - Boston Commerce says it is not a large corporate for FY2026; borrowings are below ₹1,000 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5e9626c-d02e-4870-ab4c-2e61a133e17c.pdf) |
| 30 Apr - Boston Commerce says it is not a large corporate for FY2026; borrowings are below ₹1,000 crore. | [Non-Applicability Of Disclosure Of Large Corporate For The Year Ended 31St March, 2026 30 Apr - Boston Commerce says it is not a large corporate for FY2026; borrowings are below ₹1,000 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d5e9626c-d02e-4870-ab4c-2e61a133e17c.pdf) |
| 24 Feb - EDQM issued CEP for Clopidogrel Besilate on 23 Feb 2026; adds to existing Clopidogrel Bisulphate CEP. | [EDQM Issued CEP Certificate For 'CLOPIDOGREL BESILATE' 24 Feb - EDQM issued CEP for Clopidogrel Besilate on 23 Feb 2026; adds to existing Clopidogrel Bisulphate CEP.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/540754f1-f532-4039-a618-af5c968522b4.pdf) |
| 2 Mar - Ethyl Acetate 100k→120k MTPA; Acetic Anhydride 25k→32k MTPA. Capex Rs4cr and Rs5.71cr; completed 2 Mar 2026. | [Disclosure Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 2 Mar - Ethyl Acetate 100k→120k MTPA; Acetic Anhydride 25k→32k MTPA. Capex Rs4cr and Rs5.71cr; completed 2 Mar 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6e9d370-8485-43c0-a08a-304170998922.pdf) |
| 17 Feb - Company name changed to Boston Commerce Limited from Boston Bio Systems, effective Feb 20, 2026; scrip code unchanged. | [Name Change Of The Company From BOSTON BIO SYSTEMS LIMITED To BOSTON COMMERCE LIMITED 17 Feb - Company name changed to Boston Commerce Limited from Boston Bio Systems, effective Feb 20, 2026; scrip code unchanged.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b584429-9bd9-4020-bb52-58859d735823.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-21 | [Intimation Regarding Cancellation Of Board Meeting Scheduled To Be Held On Friday 21St August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dcc0df94-825a-4e5f-88c8-2082319a2a52.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=295610dc-809b-494f-9636-13034e3079b4.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60edac10-2a7f-47d5-b112-62a8efab5462.pdf) |
| 2026-08-14 | [Intimation Of Resignation Of Secretarial Auditor](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b229d3ca-7254-4e21-8a58-73ea693bb212.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0771b13-6330-43b5-add3-cfad9da3c6f5.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0e5f338-82da-4d70-bd7b-0dd401e3cb4c.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5f7a73c-6775-473e-bea1-78e144483fde.pdf) |
| 2026-08-10 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 14Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b3b733f-cd9d-4462-9433-480cb753cde0.pdf) |
| 2026-08-07 | [Submission Of Scrutinizers Report Of The Extra Ordinary General Meeting Of Boston Commerce Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d24beb9-c5a3-4571-89a6-4f07a60486fc.pdf) |
| 2026-08-07 | [Submission Of Voting Results Under Regulation 44(3) Of The SEBI (LODR) Regulations 2015 Of EGM Held On 5Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf8d3363-8d8c-4671-969c-355c540f753c.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-06-24 | [Revised Submission Of Financial Results 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e40c84a-8301-4366-b0bf-051d15af70d9.pdf) |
| 2026-06-10 | [Revised Financial Results For Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d52136b-2309-4061-a773-d94687d068c4.pdf) |
| 2026-05-30 | [Financial Results For The Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e04b0fae-56aa-4928-b21e-dda6886e38e2.pdf) |
| 2026-02-13 | [Unaudited Financial Results For The Quarter Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1612eba9-4b58-46d3-a253-345443c91945.pdf) |
| 2025-11-14 | [Considered And Approved The Standalone Un-Audited Financial Results Of The Company For The Quarter And Half Ended On 30Th September 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a502d65c-f99d-440b-8514-6c0044231a9d.pdf) |
| 2025-08-14 | [Un-Audited Financial Results For The Quarter Ended 30Th June 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=973e39bb-92d9-4d35-a573-bffe9707fa59.pdf) |
| 2025-05-30 | [Board Meeting Outcome for Please Find Enclosed Herewith Outcome Of The Board Meeting For Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=20d12f2b-6f7d-47d3-8e1d-a87a87bd2d3f.pdf) |
| 2025-05-30 | [Please Find Enclosed Herewith Audited Results Of The Company For The Financial Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2b1a2ca-b45c-46c6-8f91-775c4c7afa4b.pdf) |
| 2025-02-24 | [Results-Delay in Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41216149-e5f9-44b9-a250-9ec0ed378053.pdf) |
| 2025-02-14 | [Outcome Of The Board Meeting Pursuant To Regulation 30 And Regulation 33 Of SEBI(Listing Obligations And Disclosure Requirement)Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91f2c801-485b-430a-ae64-30747cecf564.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/94dc8ddb-b216-4d23-a04c-7778ad2f7951.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e89694a5-3b06-45b8-b3dd-9b51bd52884d.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/19fb3bea-9b8c-4f80-9ac2-5f737bfff43b.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c360dc0-5af7-471e-a222-3bb690fd9211.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8f528fc8-e937-4ad1-b998-6dde67fcfd1a.pdf) |
| Nov 2020 | [Concall - Nov 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6442e36-d00d-4fb5-aaa9-ef3a7cc5fa6a.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/882c5ebc-c90d-4d32-8c26-c8fb487750d1.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d97f031c-fe8d-4906-baba-bfb7ebb45612.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/664d1893-4c50-469b-b2e4-8ec6c6434d01.pdf) |
| Mar 2021 | [Concall - Mar 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/54b079b8-a3f0-41db-b246-3fc43cf3570b.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cc0de24d-5d21-46ac-91f5-840c4877eba2.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d42f8861-0312-4bd7-9bc0-e8b44e7fd8cc.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/214ffd8b-127d-4a4b-b7e9-4742b1996d1d.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09dc70eb-6fec-4aa5-8ffe-40f4507ce0bb.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/754e3c9b-64fa-4430-b0b1-f7817ed50c28.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524164/74075524164.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524164/69830524164.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524164/65407524164.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524164/5241640319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524164/5241640318.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:24.077Z.